Cardiovascular (CV) outcomes trials have suggested that glucagon-like peptide-1 receptor agonists, such as semaglutide, may affect kidney-related outcomes in people with T2D
Because no head-to-head trial exists, no one can validly claim that retatrutide beats cagrilintide (or vice versa) by any specific margin
How long will it take to see results with Tirzepatide
Researchers have found diseases including cardiovascular disease, non-alcoholic fatty liver disease, diabetic chronic kidney disease, osteoarthritis, autoimmune disease, alcohol use disorder and more could be positively impacted by GLP-1RA therapy
Koje namirnice prirodno podiu nivo glutationa u telu
Roberto Piacentini, their research in Advanced Materials uses gold nanoparticles for targeted lithium delivery to the brain, this work opens new doors for treating neuropsychiatric and neurodegenerative diseases